CD14-159C/T and TLR9-1237T/C polymorphisms are not associated with gastric cancer risk in Caucasian populations.

Publication Type:

Journal Article

Source:

European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), Volume 18, Issue 2, p.117-9 (2009)

Keywords:

2009, ADENOCARCINOMA, Antigens, CD14, Case-Control Studies, Center-Authored Paper, Esophageal Neoplasms, European Continental Ancestry Group, Female, Gene Frequency, Genetic Predisposition to Disease, Genetics, Population, Humans, LINKAGE DISEQUILIBRIUM, Male, Poland, Polymorphism, Single Nucleotide, Promoter Regions, Genetic, Public Health Sciences Division, Risk Factors, Shared Resources, Specimen Processing Core Facility, Stomach Neoplasms, Toll-Like Receptor 9, United States

Abstract:

Host genetic factors play an important role in modifying the risk of human disease, including cancers of the upper gastrointestinal tract, with increasing interest in Toll-like receptor (TLR) signaling and the impact of genetic polymorphisms in these systems. The CD14-159C/T and the TLR9-1237T/C promoter polymorphisms have previously been shown to be associated with various inflammatory conditions including Helicobacter pylori-induced gastritis in Caucasian populations. In this study, we assessed the association of these two functional single nucleotide polymorphisms with gastric cancer in two independent Caucasian population-based case-control studies of upper gastrointestinal tract cancer, initially in 312 noncardia gastric carcinoma cases and 419 controls and then in 184 noncardia gastric carcinomas, 123 cardia carcinomas, 159 esophageal cancers, and 211 frequency-matched controls. Odds ratios were computed from logistic models and adjusted for potential confounding factors. No significant association was found between the CD14-159C/T and the TLR9-1237T/C promoter polymorphisms and increased risk of gastric cancer. Neither single nucleotide polymorphism has been assessed in a Caucasian gastric cancer case-control study before; although the CD14-159C/T polymorphism has been reported to show no apparent association with H. pylori-related gastric malignancy in a Taiwanese Chinese population. In conclusion, although our earlier preliminary studies suggested that the CD14-159C/T and the TLR9-1237T/C promoter polymorphisms increase the risk of precancerous outcomes, they do not seem to increase the risk of gastric cancer itself. This discrepancy merits further examination.